重磅利好！深夜，暴涨超596%！

Core Viewpoint - The article highlights the significant stock price surge of biotechnology company Abivax, which rose over 596% after announcing positive results for its oral drug Obefazimod in a Phase III trial for ulcerative colitis, with plans to submit for FDA approval in late 2026 [2][6]. Group 1: Company Performance - Abivax's stock price experienced a dramatic increase, reaching a peak rise of over 596% following the announcement of positive Phase III trial results for Obefazimod [2][5]. - The drug Obefazimod is a first-in-class oral small molecule that enhances miR-124 expression, which plays a role in anti-inflammatory responses, indicating potential applications for various inflammatory and viral diseases [6][7]. - Abivax faces challenges, including a small workforce of approximately 70 employees and significant annual losses, with a projected cash balance of €144.2 million, sufficient only until Q4 2025 [7]. Group 2: Market Context - The article notes a broader trend of retail investors driving up stock prices in the U.S. market, with significant increases in stocks like Krispy Kreme and GoPro, attributed to speculative trading [13][17]. - High levels of optimism among investors are indicated by a rise in the global fund manager confidence index from 3.3 to 4.3, the highest level since February [21]. - Retail investors have purchased approximately $50 billion worth of stocks in the past month, aligning with Barclays' estimates [22]. Group 3: Institutional Warnings - Several Wall Street institutions, including Goldman Sachs, have issued warnings about potential market corrections due to high-risk investor behavior and the surge in retail buying [20][21]. - Goldman Sachs identified two key warning signals: excessive optimism among investors and a significant influx of retail investor purchases [21][22]. - Despite these warnings, Goldman Sachs maintains a long-term positive outlook for the U.S. stock market, citing favorable monetary policy and tax reforms as potential growth drivers [25][27].